News BMS absorbs CAR-T partner 2seventy bio for $286m Bristol Myers Squibb has moved to take full control of the CAR-T therapy it partners with 2seventy bio, agreeing to buy the biotech for around $286m.
News Sun Pharma buys Checkpoint and its new cancer drug Sun Pharma has agreed to acquire Checkpoint Therapeutics, which recently claimed FDA approval for its first drug but is also running short on cash.
News Jazz swings further into cancer with Chimerix takeover Jazz has reached an agreement to buy Chimerix for around $935 million, adding a brain cancer drug heading for an FDA approval decision in August.
News Enhertu extends survival in advanced gastric cancer Data from a phase 3 trial of Enhertu in advanced HER2-positive gastric cancer could support wider use as a second-line therapy.
News Takeda scores with polycythemia vera drug in phase 3 trial A phase 3 win suggests Takeda's $300m wager on Protagonist's rusfertide for rare blood cancer polycythaemia vera (PV) appears to have paid off.
News Owkin launches ATLANTIS patient data mining project Owkin has partnered 20 healthcare institutions on a patient data mining project, ATLANTIS, across oncology, immunology/inflammation, and neurology.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.